Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for ABBV, AXSM and CDNA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Thursday, 26 May 2022 12:00 PM

Levi & Korsinsky, LLP

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / May 26, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ABBV Shareholders Click Here: https://www.zlk.com/pslra-1/abbvie-inc-loss-submission-form?prid=27779&wire=1
AXSM Shareholders Click Here: https://www.zlk.com/pslra-1/axsome-therapeutics-inc-information-request-form?prid=27779&wire=1
CDNA Shareholders Click Here: https://www.zlk.com/pslra-1/caredx-inc-information-request-form?prid=27779&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Thursday, May 26, 2022, Press release picture

AbbVie Inc. (NYSE:ABBV)

ABBV Lawsuit on behalf of: investors who purchased April 30, 2021 - August 31, 2021
Lead Plaintiff Deadline : June 6, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/abbvie-inc-loss-submission-form?prid=27779&wire=1

According to the filed complaint, during the class period, AbbVie Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to Abbvie's drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

Axsome Therapeutics, Inc. (NASDAQ:AXSM)

AXSM Lawsuit on behalf of: investors who purchased December 30, 2019 - April 22, 2022
Lead Plaintiff Deadline : July 12, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/axsome-therapeutics-inc-information-request-form?prid=27779&wire=1

According to the filed complaint, during the class period, Axsome Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07, the Company's medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application ("NDA") on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration ("FDA") reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

CareDx, Inc. (NASDAQ:CDNA)

This lawsuit is on behalf of all persons or entities who purchased CareDx common stock between February 24, 2021, and May 5, 2022.
Lead Plaintiff Deadline : July 22, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/caredx-inc-information-request-form?prid=27779&wire=1

According to the filed complaint, (1) defendants had engaged in a variety of improper and illegal schemes to inflate testing services revenue and demand, including pushing a surveillance protocol through inaccurate marketing materials, offering extravagant inducements or kickbacks to physicians and other providers, and improperly bundling expensive testing services with other blood tests as part of the Company's RemoTraC service for remote, home-based, blood-drawing; (2) these practices, and others, subjected CareDx to an undisclosed risk of regulatory scrutiny; (3) these practices rendered the Company's testing services revenue reported throughout the class period artificially inflated; and (4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: